Search

for
Search:

Sort by

Research

270-300 / 1000+ results

Synthesis and In Vitro Study of 17β-[N-Ureylene-N,N′-Disubstituted]-4-Methyl-4-Aza-5α-Androstan-3-Ones as Selective Inhibitors of Type I 5α-Reductase

research Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase

5 citations , February 1997 in “Bioorganic & Medicinal Chemistry”

New compounds were made that effectively block a specific enzyme related to androgen conditions.

research Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature

14 citations , January 2020 in “Archivio Italiano di Urologia e Andrologia”

Finasteride helps with prostate symptoms but may cause sexual side effects.

C19 and C21 5β/5α Metabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency

research C₁₉and C₂₁5β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*

55 citations , March 1990 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.

research Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know?

111 citations , August 2015 in “Reviews in Endocrine and Metabolic Disorders”

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

Comparison of Finasteride, a 5α Reductase Inhibitor, and Various Commercial Plant Extracts in In Vitro and In Vivo 5α Reductase Inhibition

research Comparison of finasteride (proscar®), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition

124 citations , January 1993 in “The Prostate”

Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.

research Inhibition of 5α-reductase alters pregnane metabolism in the late pregnant mare

7 citations , January 2018 in “Reproduction”

Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.

research Equine 5α-reductase activity and expression in epididymis

14 citations , July 2016 in “Journal of Endocrinology”

The equine epididymis mainly uses type 1 5α-reductase, and both finasteride and dutasteride can inhibit its activity.

research Study the 5α-reductase Inhibitory Activity of Urtica fissa E. Pritz's Extract

January 2009 in “Lishizhen Medicine and Materia Medica Research”

Urtica fissa extract can inhibit 5α-reductase activity.

research Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing

November 2025 in “Drug Testing and Analysis”

Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.

research Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride

10 citations , October 2010 in “International Journal of Andrology”

Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.

research PD16-01 NEW INSIGHT OF PSA REDUCTION DURING FINASTERIDE THERAPY

March 2015 in “The Journal of Urology”

Finasteride reduces PSA levels by around 40-50% in BPH patients.

research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING

April 2019 in “The Journal of urology/The journal of urology”

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population-Based Studies Using the Clinical Practice Research Datalink

research Re: Risk of Erectile Dysfunction Associated with Use of 5α-Reductase Inhibitors for Benign Prostatic Hyperplasia or Alopecia: Population Based Studies Using the Clinical Practice Research Datalink

2 citations , April 2017 in “European Urology”

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors

27 citations , July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology”

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

research Duration of finasteride and dutasteride treatment linked to long-term erectile dysfunction

January 2017 in “Clinical pharmacist”

Long use of finasteride and dutasteride can cause long-term erection problems.

research Efeitos da finasterida sobre culturas de células epiteliais prostáticas normais e tumorais em diferentes sistemas in vitro

February 2013 in “Americanae (AECID Library)”

Finasteride may reduce prostate tumor cell invasion and spread.

research Synthesis and 5α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-diene or 4,6-diene 20-ones and 4-Azasteroid 20-Oximes

186 citations , December 2011 in “Molecules”

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

research Molecular interactions of progesterone derivatives with 5α-reductase types 1 and 2 and androgen receptors

19 citations , March 2010 in “Steroids”

Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.

research Market Analysis of 5α-Reductase Inhibitor

January 2006 in “Zhongguo yaofang”

The market for these drugs is expected to grow.

5α-Reductase Inhibitors: Progress and Therapeutic Potential

research 5α-reductase inhibitors

5 citations , January 2001 in “Advances in protein chemistry”

5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.

research Intracavernous injection of platelet‐rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging‐induced erectile dysfunction rat model

12 citations , March 2023 in “The FASEB Journal”

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor

April 2011 in “Cancer Research”

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

research Long-Term Experience With 5-alpha-Reductase Inhibitors.

6 citations , January 2003 in “PubMed”

Finasteride reduces prostate size and symptoms with few side effects.

research Steroid 5α-Reductase Inhibitors

42 citations , May 2003 in “Mini-reviews in Medicinal Chemistry”

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

research Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation

19 citations , September 2013 in “Psychoneuroendocrinology”

Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.

research A New Look at the 5á-Reductase Inhibitor Finasteride

January 2006

Finasteride, a medication, is being re-evaluated for its effects and uses.

research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?

4 citations , September 2002 in “Der Urologe”

Combination therapy is more effective for prostate volumes over 60 ml.

Changes in Urine Androgen and Prostaglandin Levels During Finasteride Treatment

← Previous page Next page →